Inovio and geneone life science report positive phase 1/2a clinical data with dna vaccine ino-4700 for mers coronavirus

Inovio and geneone life science report positive phase 1/2a clinical data with dna vaccine ino-4700 for mers coronavirus at the american society of gene & cell therapy (asgct) conference.inovio pharmaceuticals inc - ino-4700 (gls-5300) dna vaccine demonstrates 100% binding and 92% neutralizing antibody responses against mers-cov.inovio - ino-4800 dna vaccine for covid-19 currently in phase 1 trial uses identical strategy targeting spike protein, cellectra intradermal delivery.inovio - planning to advance ino-4700 into a phase 2 clinical trial in middle east with funding by coalition for epidemic preparedness innovations.
INO Ratings Summary
INO Quant Ranking